Prevalence and survival of smouldering Waldenström macroglobulinaemia in the United States

Pophali, Priyanka A.; Bartley, Adam C.; Kapoor, Prashant; Gonsalves, Wilson I.; Ashrani, Aneel A.; Marshall, Ariela L.; Siddiqui, Mustaqeem; Kyle, Robert A.; Go, Ronald S.

doi:10.1111/bjh.15201

Cited by 23 publications

(16 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As there is no evidence of an increased incidence of WM from epidemiological studies, our hypothesis is that more diagnoses have been made in the last decade as a result of increasing disease awareness and increasing tendency to perform bone marrow biopsies in the diagnostic work‐up of young patients with a serum IgM monoclonal gammopathy, albeit asymptomatic. This hypothesis is supported by the higher proportion of asymptomatic WM patients observed in this study as compared with previous reports 12,13 …”

Section: Discussionsupporting

confidence: 91%

“…The study cohort included 160 young WM patients, 43 (27%) diag- reports. 12,13 The first aim of the study was to assess the pattern of treatment, including the proportion of patients treated frontline with immunotherapy-containing regimens, the proportion of patients receiving ibrutinib and the proportion of patients undergoing autologous transplantation during the course of their disease.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Younger patients with Waldenström Macroglobulinemia exhibit low risk profile and excellent outcomes in the era of immunotherapy and targeted therapies

et al. 2020

View full text Add to dashboard Cite

We analyzed 160 young Waldenström Macroglobulinemia (WM) patients with a median age of 49 years (range 23-55 years), diagnosed between January 2000 and January 2019 in 14 Italian centers. At diagnosis, 70% of patients were asymptomatic. With a median follow-up of 5.6 years, 57% have been treated. As initial therapy 79% of patients received chemo-immunotherapy, 13% a chemo-free induction and 8% chemotherapy only. At relapse or progression, 6% underwent an autologous

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Resultsmentioning

confidence: 99%

Younger patients with Waldenström Macroglobulinemia exhibit low risk profile and excellent outcomes in the era of immunotherapy and targeted therapies

et al. 2020

View full text Add to dashboard Cite

show abstract

“…We observed a three times higher incidence of WM in Sweden (11·5 per million persons per year) and an even higher incidence in northern Sweden (Brandefors et al , ). Contributing factors to this could be that Sweden has a mandatory cancer registry and a high proportion of WM patients with asymptomatic disease at diagnosis are followed with a “watch and wait” policy (73·4%), while the corresponding figure in the literature is approximately one‐quarter of the patients (Pophali et al , ). Counties with a low incidence (≤0·7) had more symptomatic patients requiring therapy at diagnosis than counties with a high incidence (≥1·2), 31% and 15%, respectively, and inferior survival ( P < 0·001).…”

Section: Discussionmentioning

confidence: 99%

Prognostic factors and primary treatment for Waldenström macroglobulinemia – a Swedish Lymphoma Registry study

Brandefors¹,

Melin

Lindh

et al. 2018

Br J Haematol

View full text Add to dashboard Cite

We present a nationwide prospective Swedish registry-based study of Waldenström macroglobulinaemia (WM), that focuses on incidence and survival in relation to clinical prognostic factors and primary systemic therapies. A total of 1511 patients with WM and lymphoplasmocytic lymphoma (LPL) were registered in the Swedish Lymphoma Registry (SLR) between 1 January 2000 and 31 December 2014. The age-adjusted incidence of WM/LPL was 11·5 per million persons per year, three times higher than the reported incidence worldwide. Medical records were retrieved for 1135 patients (75%). A retrospective review showed that 981 (86·1%) of these patients fulfilled the World Health Organization diagnostic criteria for WM and these patients were analysed further. The overall survival (OS) improved between two periods - 2000-2006 and 2007-2014 - with a five-year OS of 61% and 70%, respectively. Significant prognostic factors for OS, evaluated at the time of diagnosis, were age, elevated lactate dehydrogenase level and haemoglobin ≤115 g/l for patients receiving therapy 0-3 months after diagnosis, and age, poor performance status, haemoglobin ≤115 g/l, and female sex in "watch and wait" patients (multivariable analysis). The level of the IgM monoclonal immunoglobulin had no significant prognostic value. Rituximab included in first-line therapy was associated with improved survival.

show abstract

“…About 19% to 28% of patients have asymptomatic WM 8,29 and can remain asymptomatic for several years; median time to symptom development may exceed 5 to 10 years. 8,30,31 Table 4 depicts indications to start therapy 31,32 ; however, clinical judgement is required.…”

Section: Indications For Therapymentioning

confidence: 99%

How I treat Waldenström macroglobulinemia

Dimopoulos¹,

Kastritis²

2019

Blood

View full text Add to dashboard Cite

show abstract

Prevalence and survival of smouldering Waldenström macroglobulinaemia in the United States

Cited by 23 publications

References 10 publications

Younger patients with Waldenström Macroglobulinemia exhibit low risk profile and excellent outcomes in the era of immunotherapy and targeted therapies

Younger patients with Waldenström Macroglobulinemia exhibit low risk profile and excellent outcomes in the era of immunotherapy and targeted therapies

Prognostic factors and primary treatment for Waldenström macroglobulinemia – a Swedish Lymphoma Registry study

How I treat Waldenström macroglobulinemia

Contact Info

Product

Resources

About